Evidence map›Paper›PMID 39242587›Full record

ReviewNPJ vaccines2024

Progress on the research and development of plague vaccines with a call to action.

E Diane Williamson, Paul B Kilgore, Emily K Hendrix, Blake H Neil, Jian Sha, Ashok K Chopra

Abstract readReview
In one paragraph

Review in NPJ vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Virulence Reduction inBiomolecules · 2025
    Article
  5. rLVS ΔHuman vaccines & immunotherapeutics · 2025
    Article
  6. Review
  7. Emerging and Pandemic Pathogens: Lessons Learned From a Clinical Research Network.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025
    Review
  8. Article
  9. Novel Bivalent mRNA-LNP Vaccine for Highly Effective Protection against Pneumonic Plague.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  10. Article
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

E Diane WilliamsonDefence Science and Technology Laboratory, Porton Down, Salisbury, SP4 0JQ, UK. LHPPTN@dstl.gov.uk.ORCID http://orcid.org/0000-0002-0322-5972
Paul B KilgoreDepartment of Microbiology and Immunology, UTMB, Galveston, TX, 77555, USA.
Emily K HendrixDepartment of Microbiology and Immunology, UTMB, Galveston, TX, 77555, USA.
Blake H NeilDepartment of Microbiology and Immunology, UTMB, Galveston, TX, 77555, USA.ORCID http://orcid.org/0009-0002-8091-0604
Jian ShaDepartment of Microbiology and Immunology, UTMB, Galveston, TX, 77555, USA.
Ashok K ChopraDepartment of Microbiology and Immunology, UTMB, Galveston, TX, 77555, USA. achopra@utmb.edu.

Funding

Immunological characterization of rationally-designed vaccines against plague in mice and non-human primate modelsR01AI153524 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI CHOPRA, ASHOK K · 2021 to 2025
$3.1M
Biodefense Training ProgramT32AI060549 · NIAID · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI ASHOK K CHOPRA, Janice J Endsley · 2004 to 2026
$3.0M
Texas Medical Center Training Program in Antimicrobial ResistanceT32AI141349 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI GARSIN, DANIELLE A · 2019 to 2023
$1.3M
Antimicrobial Resistance Training Program in the Texas Medical Center (AMR-TPT)T32AI179595 · NIAID · METHODIST HOSPITAL RESEARCH INSTITUTE · PI Cesar Augusto Arias · 2024 to 2026
$1.0M
NIAID NIH HHS R01 AI153524NIAID NIH HHS T32 AI060549NIAID NIH HHS T32 AI141349
6 · The paper itself

Abstract

There is a compelling demand for approved plague vaccines due to the endemicity of Yersinia pestis and its potential for pandemic spread. Whilst substantial progress has been made, we recommend that the global funding and health security systems should work urgently to translate some of the efficacious vaccines reviewed herein to expedite clinical development and to prevent future disastrous plague outbreaks, particularly caused by antimicrobial resistant Y. pestis strains.Content includes material subject to Crown Copyright © 2024.This is an open access article under the Open Government License ( http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/ ).

Identifiers

PMID39242587
PMCPMC11379892

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.